Chee Ping CHONG, Shing Chyi LOO

Exploring The Concurrent Use and Potential Interactions Between Prescription Drugs and Health Supplement Products Among Patients With Chronic Diseases

The concurrent use of prescription drugs and health supplement products (HSP) is a concern among patients with chronic diseases. This study aimed to investigate the concurrent use of prescription drugs and HSP among patients with chronic diseases in suburban and rural area of Sarawak, Malaysia. The potential drug-HSP interactions were also assessed. This was a cross-sectional multicenter study involved seven government districts hospitals. Patients who prescribed with three or more chronic prescription drugs were recruited from the outpatient pharmacy of the hospitals by using convenient sampling. The patients’ perceptions and practices of HSP consumption were assessed by a questionnaire. The patients’ current used of prescription drugs and HSP were also assessed. A total of 350 patients were recruited in this study and 84 patients (24.0%) found to have actively using HSP. Slightly more than half (55.7%) of the patients perceived that there were potential interactions between HSP and prescription drugs. Nevertheless, 56.0% of the patients never consult their healthcare providers regarding potential drug-HSP interaction. Besides, 54.0% of patients never search for information about the potential interaction. A total of 80 cases of potential drug-HSP interactions were identified. The interactions were mostly involved antihypertensive drugs (66.3%) and antidiabetic agents (17.5%). Vitamin B3 (niacin) (33.8%) and fish oil (omega -3) supplements (26.3%) were the most common HSP involved in the interactions. In conclusion, the patients have lack of awareness regarding potential drug -HSP interactions. Healthcare providers should be alert about the concurrent use of HSP and prescription drugs among the patients.

PDF

___

1. Ismail MYM. Herb-drug interactions and patient counseling. Int Journal Pharm Pharm Sci 2009; 1: 151-161.
2. Risvoll H, Giverhaug T, Halvorsen KH, Waaseth M, Musial F. Direct and indirect risk associated with the use of dietary supplements among persons with dementia in a Norwegian memory clinic. BMC Complement Altern Med 2017; 17: 261.
3. Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA 2008; 300: 2867-2878.
4. Saw JT, Bahari MB, Ang HH, Lim YH. Potential drug-herb interaction with antiplatelet/anticoagulant drugs. Complement Ther Clin Pract 2006; 12: 236-241.
5. Chavez ML, Jordan MA, Chavez PI. Evidencebased drug-herbal interactions. Life Sci 2006; 78: 2146-2157.
6. Kupiec T, Raj V. Fatal seizures due to potential herb-drug interactions with Ginkgo biloba. J Anal Toxicol 2005; 29: 755-758.
7. Hussain MS. Patient counselling about herbaldrug interactions. Afr J Tradit Complement Altern Med 2011; 8: 152-163.
8. Fugh-Berman A. Herb-drug interactions. Lancet 2000; 355: 134-138.
9. Brazier NC, Levine MAH. Drug-herb interaction among commonly used conventional medicines: a compendium for health care professionals. Am J Ther 2003; 10: 163-169.
10. Ben-Sasson M, Levy I, Ben-Arye E, Attias S, Schiff E. Dietary and herbal supplements use among patients hospitalized in internal medicine departments. Complement Ther Med 2020; 50: 102345.
11. Valli G, Giardina EGV. Benefits, adverse effects and drug interactions of herbal therapies with cardiovascular effects. J Am Coll Cardiol 2002; 39: 1083-1095.
12. Mahfudz AS, Chan SC. Use of complementary medicine amongst hypertensive patients in a public primary care clinic in Ipoh. Med J Malaysia 2005; 60: 454-459.
13. Saw JT, Bahari MB, Ang HH, Lim YH. Herbal use amongst multiethnic medical patients in Penang Hospital: Pattern and perceptions. Med J Malaysia 2006; 61: 422-432.
14. Institute for Public Health. National Health and Morbidity Survey 2014: Malaysian Adult Nutrition Survey (MANS) Vol. II: survey findings. Kuala Lumpur: Ministry of Health Malaysia, 2014.
15. Gardiner P, Phillips R, Shaughnessy AF. Herbal and dietary supplement-drug interactions in patients with chronic illnesses. Am Fam Physician 2008; 77: 73-80.
16. Zhang Q, Zhu Z, Ni Y. Interaction between aspirin and vitamin C with human serum albumin as binary and ternary systems. Spectrochim Acta A Mol Biomol Spectrosc 2020; 236: 118356.
17. Yang B, Shi L, Wang A, et al. Lowering effects of n-3 fatty acid supplements on blood pressure by reducing plasma angiotensin II in Inner Mongolia hypertensive patients: a double-blind randomized controlled trial. J Agric Food Chem 2019; 67:184-192.
18. Ulbricht EC. Natural Standard Herb & Supplement Guide. An Evidence-Based Reference (1st ed). Missouri: Mosby Elsevier, 2010.
19. Goldberg RB, Jacobson TA. Effects of niacin on glucose control in patients with dyslipidemia. Mayo Clin Proc 2008; 83: 470- 478.
20. Xiang D, Zhang Q, Wang Y. Effectiveness of niacin supplementation for patients with type 2 diabetes. Medicine (Baltimore) 2020; 99: e21235.
21. Jain RK, McCormick JC. Can glucosamine supplements be applied for all patients with type 2 diabetes with osteoarthritis? Arch Intern Med 2004; 164: 807.
22. Biggee BA, Blinn CM, Nuite M, Silbert JE, McAlindon TE. Effects of oral glucosamine sulphate on serum glucose and insulin during an oral glucose tolerance test of subjects with osteoarthritis. Ann Rheum Dis 2007; 66: 260- 262.
23. Omar M, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 2002; 36: 288-295.
24. Reaven P, Witztum JL. Lovastatin, nicotinic acid, and rhabdomyolysis. Ann Intern Med 1988; 109: 597-598.
25. Guyton JR. Combination drug therapy for combined hyperlipidemia. Curr Cardiol Rep 1999; 1: 244-250.
26. Merck Sharp & Dohme Corp. Vytorin - ezetimibe and simvastatin tablet. Highlights of Prescribing Information. Whitehouse Station: Merck & Co., Inc., 2019.
27. Tsai H, Lin H, Lu Y, Chen Y, Mahady GB. A review of potential harmful interactions between anticoagulant/antiplatelet agents and Chinese herbal medicines. PLoS One 2013; 8: e64255.
28. Abebe W. Herbal medication: potential for adverse interactions with analgesic drugs. J Clin Pharm Ther 2002; 27: 391-401.
29. Indermitte J, Burkolter S, Drewe J, Krähenbühl S, Hersberger KE. Risk factors associated with a high velocity of the development of hyperkalaemia in hospitalised patients. Drug Saf 2007; 30: 71-80.
30. Novartis Pharmaceuticals Corporation. Product Information: Diovan® (valsartan) oral tablets. East Hanover: Novartis Pharmaceuticals Corporation, 2007.
31. Foley H, Steel A, Cramer H, Wardle J, Adams J. Disclosure of complementary medicine use to medical providers: a systematic review and meta-analysis. Sci Rep 2019; 9: 1573.
32. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997: results of a followup national survey. JAMA 1998; 280: 1569- 1575.
33. Alshagga MA, Al-Dubai SA, Muhamad Faiq SS, Yusuf AA. Use of complementary and alternative medicine among asthmatic patients in primary care clinics in Malaysia. Ann Thorac Med 2011; 6: 115-119.
34. Hasan SS, Ahmed SI, Bukhari NI, Cheah WWL. Use of complementary and alternative medicine among patients with chronic diseases at outpatient clinics. Complement Ther Clin Pract 2009; 15: 152-157.
35. Tachjian A, Maria V, Jahangir A. Use of herbal products and potential interactions in patients with cardiovascular diseases. J Am Coll Cardiol 2010; 55: 515-525.
36. Morris CA, Avorn J. Internet marketing of herbal products. JAMA 2003; 290: 1505-1509.